Covid inquiry: UK's public services were 'depleted' when Covid hit
The nation’s health was declining and the NHS was struggling by 2020, the Covid inquiry hears.
Similar Posts
Johnson & Johnson (JNJ) earnings Q4 2023
The stock trading graph of Johnson & Johnson is seen on a smartphone screen. Rafael Henrique | SOPA Images | LightRocket | Getty Images Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations as sales in the company’s pharmaceutical and medical devices businesses surged. J&J also provided full-year…
FDA approves first at-home sterile insemination kit to help with infertility: ‘Gives me goosebumps’
Join Fox News for access to this content Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the…
Why Covid is still flooring some people
A lot of us know someone who has felt pretty rough with the most recent form of the virus.
Health sector themes to watch in 2024
An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and…
Ask a doc: ‘When is a cough something to worry about?’
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
J&J to acquire Ambrx Biopharma, a cancer drug developer, for $2B
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment….